📅 PUBMED DAILY TRIAGE — 2026-05-18
Window: 2026-05-17T09:00:00Z → 2026-05-18T09:00:00Z (CRDT) Topics scanned: 10 | Articles reviewed: ~28 | Candidates evaluated: ~42 raw PMIDs High priority: 2 | Standard: 12 | Low/archive: 4 | Unsolicited finds: 1 Run status: SUCCESS
🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic
Novel Therapeutics: Immunotherapy / CAR-T | Hematologic Malignancies
TR-2026-05-18-001 / PMID 42144261 · Clinical outcomes and spatial transcriptomic profiles of CD19/20 CAR-T therapy in relapsed or refractory B-cell non-Hodgkin's lymphoma · 8/10 🟠 NOVEL_TREATMENT
Phase I/II (n=32 R/R B-NHL): bispecific CD19/20 CAR-T achieved 74% ORR, 58% CR, mOS 22.1 months; spatial transcriptomics identified two tumor architectures predicting durable vs partial responses — a meaningful step toward pre-treatment patient stratification for CAR-T.
Early Cancer Detection (cfDNA / Liquid Biopsy) | AI/ML in Diagnostics
TR-2026-05-18-002 / PMID 42143451 · Semantic inductive graph-based diagnostics: A category-aware NLP-GCN framework for robust cancer detection via cfDNA end-motif and fragmentation analysis · 8/10 🔴 EARLY_CANCER_DETECTION
Validation cohort of 2,451 plasma samples; GCN+BiLSTM (SIGD) framework achieved AUROC 0.967 pan-cancer and 0.998 for HCC via cfDNA fragmentation patterns; inductive design enables real-time inference without per-cohort retraining.
🟢⚪ STANDARD (5–7) — Top by Topic
Hematologic Malignancies
- TR-2026-05-18-003 / 42144574 · Pediatric non-DS AMKL: FLAG-IDA + MRD-guided HSCT in CR1 · 6/10 · Treatment Innovation (retrospective, n=58, multicenter China; 5-yr OS 61.7%)
- TR-2026-05-18-004 / 42144191 · ASTCT consensus: biomarker testing with CAR-T (ASTCT multidisciplinary expert panel) · 7/10 · Diagnostics/Near-Term Implementable (must-have/can-have tiers for cytokine + CAR-T kinetic monitoring)
- TR-2026-05-18-005 / 42144172 · scRNA-seq atlas of CD8+ T cells in DLBCL TME (systematic review, 18 studies) · 6/10 · Genomics/Precision Medicine (Tpex = favorable prognosis; CD58 loss = CAR-T resistance biomarker)
- TR-2026-05-18-006 / 42144302 · T-ALL novel therapies review (nelarabine, CAR-T, daratumumab) · 5/10 · Treatment Innovation (Review; AALL0434: 92.2% 4yr DFS with nelarabine)
Novel Therapeutics
- TR-2026-05-18-008 / 42144533 · CAR-neutrophils from iPSC: new frontier in cellular immunotherapy · 5/10 · Drug Development (review; iPSC-CAR-Neut as scalable cell source for solid tumor immunotherapy)
- TR-2026-05-18-014 / 42144527 · Immunometabolism in TME: metabolic battle between cancer and immune cells · 4/10 · Treatment Innovation (review chapter; TME metabolic suppression limiting CAR-T/ICI efficacy)
AI/ML in Clinical Diagnostics
- TR-2026-05-18-007 / 42144453 · RDE-DR deep ensemble CNN for diabetic retinopathy · 5/10 · Diagnostics (benchmark study; 99.78% AUC on APTOS 2019; single-dataset limitation)
Cardiovascular-Metabolic
- TR-2026-05-18-009 / 42144570 · GRC Study: Genetics of Response to Canagliflozin (n=402 Amish) · 7/10 · Genomics/Precision Medicine (34% heritability of glucosuria; pharmacodynamic characterization of bone/CVD/ketosis markers)
Aging / Longevity
- TR-2026-05-18-010 / 42144546 · Fisetin attenuates doxorubicin-induced premature vascular aging via senolysis · 5/10 · Prevention (mouse + human cells; reversed endothelial dysfunction p<0.001; score capped — primary model non-human)
Rare Diseases
- TR-2026-05-18-011 / 42144266 · Natural history of Morquio A syndrome: endpoint gaps and unmet need · 6/10 · Diagnostics/Rare Disease (J Inherit Metab Dis; highlights need for non-invasive quantitative endpoints across phenotypic spectrum)
- TR-2026-05-18-012 / 42144551 · RDCRN collaboration model for rare disease research · 4/10 · Public Health (descriptive; methodological value for trial readiness infrastructure)
💡 UNSOLICITED FINDS
- TR-2026-05-18-013 / PMID 42144576 · Hypertension, Dyslipidemia, and Adhesive Capsulitis: Bidirectional MR Study · 4/10 · Interesting MR finding: AC → ↓HDL and ↑apoB/A1 (reverse causality). Out-of-watchlist; flagged for awareness only.
📊 TODAY'S BREAKDOWN
By research category:
- Treatment Innovation: 5
- Diagnostics: 4
- Genomics/Precision Medicine: 2
- Drug Development: 1
- Prevention: 1
- Public Health: 2
By evidence maturity:
- Validated: 5
- Exploratory: 7
- Potentially Practice-Changing: 0
By watchlist topic (reviewed / kept / highest score):
| Topic | Reviewed | Kept | Best Score |
|---|---|---|---|
| Hematologic malignancies | 7 | 5 | 8 |
| CBC + ML in hematology | 2 | 1 | 5 |
| Early cancer detection (cfDNA) | 2 | 2 | 8 |
| AI/ML clinical diagnostics | 5 | 2 | 5 |
| Precision oncology/genomics | 2 | 1 | 7 |
| Novel therapeutics (CAR-T/immunotherapy) | 5 | 4 | 8 |
| Cardiovascular-metabolic (SGLT2/GLP-1) | 3 | 2 | 7 |
| Aging/longevity (humans[MeSH]) | 2 | 1 | 5 |
| Rare diseases | 2 | 2 | 6 |
| Sentinel scan | 2 | 1 | 4 |
By source type: peer_reviewed: 14 | preprint: 0
Topics with zero 8+ articles today: CBC/hematology ML, AI/ML diagnostics, Precision oncology, Cardiovascular-metabolic, Aging/longevity, Rare diseases
🔧 RUN NOTES
- Window: Incremental CRDT 2026-05-17T09:00Z → 2026-05-18T09:00Z. No window expansion needed (kept >5 relevant records across topics).
- Monday indexing: Moderate volume. Broad sentinel scan returned 150 hits; capped at 10 for review; heavy overlap with immunotherapy/oncology topics already covered.
- Aging/longevity filter: humans[MeSH] maintained per v1.2 note. Returned 7 results; top result was doxorubicin/fisetin study (mixed human/mouse model) — included due to human cell component.
- AI/ML search (33 hits): Dominated by benchmark ML imaging papers; most scored ≤5; only DR detection paper and cfDNA SIGD kept.
- Immunotherapy/cancer search (35 hits): Several book chapters from Cancer Treatment and Research vol. 195 indexed today (metabolic oncology theme issue); scored 4–5 STANDARD.
- No window expansion triggered (≥5 relevant records found).
- Rolling 7-day zero-HIGH topics: CBC/hematology ML has produced 0 HIGH articles for the last 3 runs. Suggest broadening query or adjusting to sub-threshold keep for next run.
- 2 Telegram alerts sent (HIGH threshold met).